Novo bolsters R&D pipeline with RNAi therapies from Dicerna

Novo Nordisk has further bolstered its liver disease R&D pipeline, signing a deal with US biotech Dicerna to discover and develop RNA-blocking therapies for diseases such as NASH and ty

Novo Nordisk buys rights to NASH drug from Japan's UBE

Novo Nordisk has acquired rights to a preclinical drug that could be used to treat non-alcoholic steatohepatitis (NASH), the fatty liver disease that could generate billions of dollars for

Novo Nordisk builds in haemophilia with Bluebird Bio gene ed...

How to make digital adoption a smooth journey

Four big pharma experts explain the challenges companies face in adopting digital tech and what trends are likely to drive digital commercial strategies in the next few years.

Novo’s new oral GLP-1 Rybelsus still has obstacles to overco...

The Pharma Comms Impact Conference - For Internal & External

20 Pharmaceutical Communications Senior Speakers, 1 Day